HOME >> BIOLOGY >> NEWS
First Study To Take Bacteria Directly From Patients' Mouths Further Supports Possible Link Between Gum And Heart Disease

By taking bacteria samples directly from patients' mouths and exposing the samples to human blood platelets, researchers at Temple Univeristy Schools of Dentistry and Medicine have further confirmed a possible link between periodontal bacteria and heart disease.

In recent weeks, a great deal of media attention has been focused on this possible relationship. In fact, since the early 1990s, preliminary studies at other universities have used laboratory strains of mouth bacteria and population data to show this possible link.

Temple's study is the first to take a large number of dental plaque bacteria directly from the mouths of patients with severe periodontal disease and test their effect on blood platelets.

"Almost immediately after we exposed human blood platlets to the dental plaque bacteria, the platelets began to clump together," says Dr. Eugene J. Whitaker, associate professor of Dentistry and lead investigator. "And, out of all the periodontal bacteria we tested, Porphyromanas gingivalis was the only one to cause this clumping, which is a key step in formation of bloodstream thrombi (blockage)."

Porphyromanas gingivalis is the most important bacterial cause of destructive gum diseases in adults. The Temple research findings further support and expand a possible link between periodontal disease and development of athrosclerotic heart disease, a condition resulting from plaque build-up and constriction of coronary heart arteries, and strokes affecting the brain.

"The importance of our findings is that at least 36 million American adults have some form of destructive periodontal disease, which leads to loosening and loss of teeth," says Dr. Thomas E. Rams, a co-investigator and chairman of Temple's Department of Periodontology. "Porphyromanas gingivalis is very frequently in dental plaque causing this disease. These people may be at increased risk
'"/>

Contact: Andrew Smith
asmith01@nimbus.ocis.temple.edu
(215) 707-8229
Temple University Health System
27-Feb-1998


Page: 1 2

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
(Date:3/3/2015)... , March 3, 2015 Fried, Frank, Harris, ... I.D. Lewis has joined the Firm as a ... the New York office. Mr. ... matters, as well as other intellectual property and general ... Mr. Lewis represents both plaintiffs and defendants in a ...
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the ... under Chapter 11 of the U.S. Bankruptcy Code in the ... , Santa Ana division (the "Bankruptcy ... are expected to be jointly administered. The Company ... sale process, for all or substantially all of its assets ...
(Date:3/3/2015)... Switzerland (PRWEB) March 03, 2015 ... for drug discovery and life science research, today ... Biologics (TM) enterprise platform for use at Pfizer ... and Europe. Genedata is supporting Pfizer’s global deployment ... Technologies (GBT), Centers for Therapeutic Innovation (CTI), and ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
Cached News: